(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.36%) $78.10
(0.18%) $2.21
(0.00%) $2 324.20
(0.13%) $27.58
(-0.06%) $987.80
(0.16%) $0.931
(0.43%) $10.95
(0.19%) $0.801
(0.00%) $91.44
-0.69% $ 7.96
Live Chart Being Loaded With Signals
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland...
Stats | |
---|---|
Dzisiejszy wolumen | 336 952 |
Średni wolumen | 2.33M |
Kapitalizacja rynkowa | 875.15M |
EPS | $0 ( 2024-03-25 ) |
Następna data zysków | ( $-0.320 ) 2024-05-23 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -8.20 |
ATR14 | $0.0160 (0.20%) |
Wolumen Korelacja
Mesoblast Limited Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
PFSW | 0.949 |
LABP | 0.944 |
DSGN | 0.941 |
NN | 0.94 |
CTIC | 0.936 |
PRVB | 0.93 |
CDXC | 0.927 |
PESI | 0.927 |
IDN | 0.92 |
SCTL | 0.919 |
10 Najbardziej negatywne korelacje | |
---|---|
LIAN | -0.939 |
SBNYP | -0.928 |
LUCD | -0.923 |
LUNA | -0.922 |
NOVN | -0.912 |
NLSP | -0.909 |
AEY | -0.908 |
PRFT | -0.908 |
AZ | -0.907 |
EZGO | -0.905 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Mesoblast Limited Korelacja - Waluta/Towar
Mesoblast Limited Finanse
Annual | 2023 |
Przychody: | $7.50M |
Zysk brutto: | $-20.23M (-269.72 %) |
EPS: | $-1.050 |
FY | 2023 |
Przychody: | $7.50M |
Zysk brutto: | $-20.23M (-269.72 %) |
EPS: | $-1.050 |
FY | 2022 |
Przychody: | $10.21M |
Zysk brutto: | $-20.55M (-201.21 %) |
EPS: | $-1.330 |
FY | 2021 |
Przychody: | $7.46M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-0.817 |
Financial Reports:
No articles found.
Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej